Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Takes A Scientific Look At Hot-Button Issue Of Unannounced Foreign Inspections

Executive Summary

As Congress beats the drums for surprise inspections abroad, the agency plans a statistically rigorous comparison of announced versus unannounced inspections. Meanwhile, as authorities shed COVID-19 precautions, FDA investigators flood back into the field domestically, with surge of foreign inspections to follow soon.

You may also be interested in...



Foreign Facilities Get Details From US FDA On Avoiding ‘Refusal To Allow Inspection’ Violation

Guidance states regulatory violation of refusing to permit entry of FDA investigator to inspect or not permitting an inspection includes “statements, actions, and passive behaviors that prevent or delay us from scheduling or fully conducting an inspection.”

Surprise US FDA Facility Inspections Resume In India

Unannounced facility visits also were to start again in China, but FDA Commissioner Robert Califf said they have been delayed by the COVID-19 outbreak in the country.

House Appropriators Continue Pressing US FDA To Conduct Surprise In-Person Inspections

The bill also would give the FDA expanded authority over nicotine products and create President Biden’s Advanced Research Projects Agency for Health.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel